Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
The registrational part 2 of bezuclastinib's Summit trial reads out in July.
When your investment case breaks down, why not just do the decent thing?
A new KRAS degrader and PD-1 x Lag3 bispecific have just started phase 1.
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
The players are vying in the CD19 x CD20 Car-T arena.
